Chee‐Chee Stucky

Closest collaborators

The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Nabil Wasif · 9 shared papers, 2022–2026 · strength 2.36
   • Paper Adjuvant Chemotherapy Is Not Associated With Improved Overall Survival in Patients With Pancreatic Ductal Adenocarcinom… DOI 10.1002/jso.70414↗
   • Paper The Neoadjuvant Window: Serial Assessment of Sarcopenia During Treatment for Pancreatic Cancer. DOI 10.1177/00031348261495994↗
   • Paper The Financial Burden of Pancreatic Enzyme Replacement Therapy for Patients With Resected Pancreatic Cancer. DOI 10.1002/jso.70361↗
2. Zhi Ven Fong · 8 shared papers, 2024–2026 · strength 2.16
   • Paper Adjuvant Chemotherapy Is Not Associated With Improved Overall Survival in Patients With Pancreatic Ductal Adenocarcinom… DOI 10.1002/jso.70414↗
   • Paper The Neoadjuvant Window: Serial Assessment of Sarcopenia During Treatment for Pancreatic Cancer. DOI 10.1177/00031348261495994↗
   • Paper The Financial Burden of Pancreatic Enzyme Replacement Therapy for Patients With Resected Pancreatic Cancer. DOI 10.1002/jso.70361↗
3. Richard J. Bold · 5 shared papers, 2026 · strength 1.33
   • Paper Adjuvant Chemotherapy Is Not Associated With Improved Overall Survival in Patients With Pancreatic Ductal Adenocarcinom… DOI 10.1002/jso.70414↗
   • Paper Do Postoperative Complications Impact Adjuvant Chemotherapy in Patients Undergoing Left-Side Pancreatectomy for Pancrea… DOI 10.1245/s10434-026-19739-2↗
   • Paper ASO Visual Abstract: Do Postoperative Complications Impact Adjuvant Chemotherapy for Patients Undergoing Left-Side Panc… DOI 10.1245/s10434-026-19795-8↗
4. Dillon C. Cheung · 4 shared papers, 2026 · strength 1.09
   • Paper The Neoadjuvant Window: Serial Assessment of Sarcopenia During Treatment for Pancreatic Cancer. DOI 10.1177/00031348261495994↗
   • Paper Do Postoperative Complications Impact Adjuvant Chemotherapy in Patients Undergoing Left-Side Pancreatectomy for Pancrea… DOI 10.1245/s10434-026-19739-2↗
   • Paper ASO Visual Abstract: Do Postoperative Complications Impact Adjuvant Chemotherapy for Patients Undergoing Left-Side Panc… DOI 10.1245/s10434-026-19795-8↗
5. Yu-Hui H. Chang · 3 shared papers, 2022–2026 · strength 0.79
   • Paper Adjuvant Chemotherapy Is Not Associated With Improved Overall Survival in Patients With Pancreatic Ductal Adenocarcinom… DOI 10.1002/jso.70414↗
   • Paper The Financial Burden of Pancreatic Enzyme Replacement Therapy for Patients With Resected Pancreatic Cancer. DOI 10.1002/jso.70361↗
   • Paper Association of Textbook Outcome and Surgical Case Volume with Long-Term Survival in Patients Undergoing Surgical Resect… DOI 10.1097/xcs.0000000000000407↗
6. Stephanie Yu · 3 shared papers, 2026 · strength 0.79
   • Paper Do Postoperative Complications Impact Adjuvant Chemotherapy in Patients Undergoing Left-Side Pancreatectomy for Pancrea… DOI 10.1245/s10434-026-19739-2↗
   • Paper ASO Visual Abstract: Do Postoperative Complications Impact Adjuvant Chemotherapy for Patients Undergoing Left-Side Panc… DOI 10.1245/s10434-026-19795-8↗
   • Paper Correction: Do Postoperative Complications Impact Adjuvant Chemotherapy in Patients Undergoing Left-Side Pancreatectomy… DOI 10.1245/s10434-026-20347-3↗
7. Tanios Bekaii‐Saab · 3 shared papers, 2023–2026 · strength 0.61
   • Paper Adjuvant Chemotherapy Is Not Associated With Improved Overall Survival in Patients With Pancreatic Ductal Adenocarcinom… DOI 10.1002/jso.70414↗
   • Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
   • Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
8. Craig Lee Slingluff · 2 shared papers, 2023–2024 · strength 0.30
   • Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
   • Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
9. Matthew H. G. Katz · 2 shared papers, 2023–2024 · strength 0.30
   • Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
   • Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
10. Victoire Cardot‐Ruffino · 2 shared papers, 2023–2024 · strength 0.30
    • Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
    • Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
11. Andressa Dias Costa · 2 shared papers, 2023–2024 · strength 0.30
    • Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
    • Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
12. Rawad Elias · 2 shared papers, 2023–2024 · strength 0.30
    • Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
    • Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
13. Matthew J. Reilley · 2 shared papers, 2023–2024 · strength 0.30
    • Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
    • Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
14. Nipun B. Merchant · 2 shared papers, 2023–2024 · strength 0.30
    • Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
    • Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
15. Brian Matthew Wolpin · 2 shared papers, 2023–2024 · strength 0.30
    • Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
    • Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
16. Todd W. Bauer · 2 shared papers, 2023–2024 · strength 0.30
    • Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
    • Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
17. Osama E. Rahma · 2 shared papers, 2023–2024 · strength 0.30
    • Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
    • Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
18. Jonathan Andrew Nowak · 2 shared papers, 2023–2024 · strength 0.30
    • Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
    • Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
19. Stephanie K. Dougan · 2 shared papers, 2023–2024 · strength 0.30
    • Paper PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with … DOI 10.1158/1078-0432.ccr-23-1444↗
    • Paper Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in … DOI 10.1136/jitc-2023-007586↗
20. Mitesh J. Borad · 1 shared paper, 2026 · strength 0.30
    • Paper Adjuvant Chemotherapy Is Not Associated With Improved Overall Survival in Patients With Pancreatic Ductal Adenocarcinom… DOI 10.1002/jso.70414↗
21. Kumaresan Sandrasegaran · 1 shared paper, 2026 · strength 0.30
    • Paper The Neoadjuvant Window: Serial Assessment of Sarcopenia During Treatment for Pancreatic Cancer. DOI 10.1177/00031348261495994↗
22. Valerie L. Armstrong · 1 shared paper, 2026 · strength 0.30
    • Paper Adjuvant Chemotherapy Is Not Associated With Improved Overall Survival in Patients With Pancreatic Ductal Adenocarcinom… DOI 10.1002/jso.70414↗
23. Rahul Pannala · 1 shared paper, 2026 · strength 0.29
    • Paper The Financial Burden of Pancreatic Enzyme Replacement Therapy for Patients With Resected Pancreatic Cancer. DOI 10.1002/jso.70361↗
24. Patricia G Lu · 1 shared paper, 2026 · strength 0.29
    • Paper The Financial Burden of Pancreatic Enzyme Replacement Therapy for Patients With Resected Pancreatic Cancer. DOI 10.1002/jso.70361↗
25. Cho‐Han Chiang · 1 shared paper, 2024 · strength 0.24
    • Paper Pancreatic cancer mortality trends in the United States: how much have we moved the needle? DOI 10.21037/jgo-24-213↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.